Previous 10 | Next 10 |
- GATHER2 Enrollment and Retention Continue to Exceed Expectations; Completion of Enrollment Expected Late July of this Year and Topline Data Expected Second Half of 2022 - - Conference Call and Webcast Today, July 6, 2021, at 8:00 a.m. ET - IVERIC bio, Inc. (Nas...
IVERIC bio (ISEE) will discuss an accelerated enrollment timeline and patient retention, including injection fidelity, for GATHER2, the company’s pivotal clinical trial of Zimura in development for the treatment of geographic atrophy secondary to age-related macular degenerat...
CAI International (CAI) +46% on merger deal with Mitsubishi HC Capital.Sykes Enterprises (SYKE) +30% on being acquired by Sitel group for $54.0 per share.AnPac Bio-Medical Science (ANPC) +22% after securing first disease treatment patent in U.S.Geron Corporation (GERN) +20% ...
- GATHER2 Enrollment Nears Completion; Timeline Accelerated to Late July of this Year - - GATHER2 Retention Exceeding Expectations; with Injection Fidelity Rate Target for GATHER2 Greater than 90% - - GATHER1 18 Month Post-Hoc Analyses Show that Zimura 2 mg Has the Pot...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...
- To Provide Updates on Zimura ® GATHER2 Enrollment and Retention - - Post-Hoc Analyses from GATHER1 on Progression of Drusen and Nascent Geographic Atrophy to be Presented for the First Time – IVERIC bio, Inc. (Nasdaq: ISEE) today announced detai...
Image source: The Motley Fool. IVERIC bio, Inc. (NASDAQ: ISEE) Q1 2021 Earnings Call May 05, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: IVERIC bio, Inc. (ISEE) Q1 2021 Earnings Call Transcript
IVERIC bio, Inc. (ISEE) Q1 2021 Earnings Conference Call May 05, 2021 08:00 AM ET Company Participants Kathy Galante - Senior Vice President-Investor Relations Glenn Sblendorio - Chief Executive Officer Keith Westby - Chief Operating Officer Pravin Dugel - President David Carroll - Chief Fina...
IVERIC bio (ISEE): Q1 GAAP EPS of -$0.29 misses by $0.04.As of March 31, 2021, the Company had $180.2 million in cash, cash equivalents and available for sale securities.FY21 guidance: Cash, cash equivalents and available for sale securities will range between $125M-135M.Press Release For f...
- GATHER2 On-Track to Complete Enrollment in 3Q of this Year - - Conference Call and Webcast Today, May 5, 2021, at 8:00 a.m. ET - IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the quarter ended March 31, 2021 and provided a ...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...